Compare MXCT & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | FRD |
|---|---|---|
| Founded | 1999 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.6M | 134.3M |
| IPO Year | 2021 | 1995 |
| Metric | MXCT | FRD |
|---|---|---|
| Price | $1.18 | $23.54 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 25.9K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | ★ 0.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.46 |
| Revenue | $33,026,000.00 | ★ $121,157,278.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.50 | N/A |
| P/E Ratio | ★ N/A | $16.36 |
| Revenue Growth | N/A | ★ 55.82 |
| 52 Week Low | $0.64 | $14.52 |
| 52 Week High | $2.38 | $24.69 |
| Indicator | MXCT | FRD |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 66.39 |
| Support Level | $0.77 | $18.15 |
| Resistance Level | $1.82 | $24.37 |
| Average True Range (ATR) | 0.09 | 0.96 |
| MACD | 0.01 | 0.20 |
| Stochastic Oscillator | 60.00 | 75.74 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.